Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., appointed Charles Gorodetzky chief medical officer and Douglas Winship vice president of regulatory operations.
Cell Therapeutics Inc., of Seattle, appointed Mauro Premi acting managing director and board member of Cell Therapeutics Europe Srl. It also appointed Gabriella Pezzoni scientific director for Bresso.
Cellumen Inc., of Pittsburgh, appointed Rosemary Mazanet to its board.
Celsion Corp., of Columbia, Md., appointed Anthony Deasey interim CEO and board member.
Cephalon Inc., of Frazer, Pa., appointed Lesley Russell senior vice president, worldwide medical and regulatory operations.
Chelsea Therapeutics International Ltd., of Charlotte, N.C., appointed Horacio Kaufmann, Roy Freeman and Peter LeWitt to its scientific advisory board.
Chromos Molecular Systems Inc., of Burnaby, British Columbia, appointed Jack Antel, Dennis Bourdette, James Bowen, Lorne Kastrukoff, Joel Oger and Leslie Weiner to its multiple sclerosis advisory board.
Cobra Biomanufacturing plc, of Keele, UK, appointed John Lovelady director of manufacturing operations.
Cubist Pharmaceuticals Inc., of Lexington, Mass., appointed Gordon Archer to its board.
DOR BioPharma Inc., of Miami, appointed Christopher Schaber president and CEO.
Entelos Inc., of Foster City, Calif., appointed John Rigsbee general counsel.
GammaCan International, of Kiryat Ono, Israel, appointed Richard Spritz to its scientific advisory board.
Genaera Corp., of Plymouth Meeting, Pa., appointed Anthony DelConte vice president, clinical research and development.
Gene Express Inc., of Toledo, Ohio, appointed Nick Lazaridis president.
Genelabs Technologies Inc., of Redwood City, Calif., appointed Peter Young vice president, biology.
Genesis Bioventures Inc., of New York, appointed John Todd chairman of its clinical advisory board, and Mark Franzen chief financial officer.
Idenix Pharmaceuticals Inc., of Cambridge, Mass., appointed John Weidenbruch executive vice president and general counsel.
InNexus Biotechnology Inc., of Vancouver, British Columbia, appointed Jeff Morhet CEO and president.
Inyx Inc., of New York, appointed Roger Harrison and Peter Littmann to its board.
IsoTis SA, of Lausanne, Switzerland, appointed Gene Reu vice president of operations.
Momenta Pharmaceuticals Inc., of Cambridge, Mass., appointed Craig Wheeler CEO.
Neurologix Inc., of Fort Lee, N.J., appointed Cornelius Golding a Class II director who will serve on the company's audit committee.
Nitric BioTherapeutics Inc., of Philadelphia, appointed James Ratigan chief financial officer.
Novavax Inc., of Malvern, Pa., appointed Tom Monath director.
Nutra Pharma Corp., of Boca Raton, Fla., appointed Dorothy Bray to the ReceptoPharm scientific advisory board.
Omrix Biopharmaceuticals Inc., of New York, appointed Nanci Prado vice president and general counsel.
Osteologix Inc., of San Francisco, appointed Matthew Loar chief financial officer.
Portola Pharmaceuticals Inc., of South San Francisco, appointed Mardi Dier chief financial officer.
Prestwick Pharmaceuticals Inc., of Washington, appointed George Horner president and CEO.